Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 1, 2010, Pages 68-72

  Gozzetti, Alessandro ^a   Fabbri, Alberto ^a   Oliva, Stefania ^a   Marchini, Elena ^a   Bocchia, Monica ^a   Defina, Marzia ^a   Lauria, Francesco ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bence Jones protein; Neutropenia; Paresthesia; Proteasome inhibitor

Indexed keywords

ACICLOVIR; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; MACROGOL DERIVATIVE; PYRAZINE DERIVATIVE;

AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; MORTALITY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DOXORUBICIN; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; POLYETHYLENE GLYCOLS; PYRAZINES;

EID: 77954071555     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.008     Document Type: Article

References (17)

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe. Ann Oncol 2004; 16:481-8
2. Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med 2004; 351:1860-73.
3. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-72. (Pubitemid 39371809)
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17. (Pubitemid 36741588)
5. Richardson PG, Barlogie B, Berenson J, et al SUMMIT Investigators. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005; 106:2977-81. (Pubitemid 41565888)
6. Richardson PG, Sonnoveld P, Schuster MW, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98.
7. Manochakian R, Miller KC, Chanan-Khan AA. Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma. Clin Lymphoma Myeloma 2007; 7:266-71. (Pubitemid 46408190)
8. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058-65.
9. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25:3892-901. (Pubitemid 47477266)
10. Brenner H, Gondos A, Pulte A. A recent major improvement in long term survival of younger patients with multiple myeloma. Blood 2008; 111:2521-6.
11. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-54.
12. Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467-73. (Pubitemid 44264086)
13. Cancer Therapy Evaluation Program [Web site]. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS 2006. Available at: http://ctep.cancer.gov. Accessed: January 4, 2010.
14. Offidani M, Corvatta L, Marconi M, et al. Low dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II. Haematologica 2006; 91:133-6. (Pubitemid 43235397)
15. Palumbo A, Gay F, Bringhen S, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008; 19:1160-5. (Pubitemid 351796343)
16. Patriarca F, Prosdocimo S, Tomadini V, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005; 90:278-9. (Pubitemid 40293302)
17. Laura R, Cibeira MT, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006; 76:405-8.